Abstract
Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a) antigen was prolonged in gastric or lung cancer patients, respectively.
Author supplied keywords
Cite
CITATION STYLE
APA
Ohue, Y., Wada, H., Oka, M., & Nakayama, E. (2014). Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients. OncoImmunology, 3(11), e970032-1-e970032-3. https://doi.org/10.4161/21624011.2014.970032
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free